Literature DB >> 622601

Role of sodium intake in the antihypertensive effect of propranolol.

C J Owens, N C Brackett.   

Abstract

Twelve hypertensive patients had measurements of body weight, blood pressure, plasma renin activity, and plasma volume during periods of normal sodium intake and acute sodium depletion. After receiving propranolol orally for four to 14 weeks, repeat measurements were obtained under identical conditions of sodium intake. During normal sodium intake, propranolol therapy was associated with a decrease in plasma renin activity, a variable tendency to an increase in body weight and plasma volume, and a decrease in mean arterial pressure of 5 mm Hg (NS). During sodium restriction, blood pressure was decreased significantly from that observed during normal sodium intake and propranolol added a further significant decrease of 8 mm Hg (P less than .01). Blood pressure reductions obtained with sodium depletion and acute diuretic therapy were approximately the same with or without propranolol. The increase in plasma renin activity expected with sodium depletion and diuretic therapy was not blunted by propranolol.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 622601     DOI: 10.1097/00007611-197801000-00013

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

Review 1.  Is salt restriction relevant and feasible as adjunctive treatment of hypertension?

Authors:  M H Weinberger
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 2.  Can non-pharmacological interventions reduce doses of drugs needed for the treatment of hypertension? World Hypertension League.

Authors: 
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

3.  Improvement of cardiovascular effects of metoprolol by replacement of common salt with a potassium- and magnesium-enriched salt alternative.

Authors:  E M Mervaala; J Laakso; H Vapaatalo; H Karppanen
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.